Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/12—Viral antigens
  • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/12—Viral antigens
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/10—Dispersions; Emulsions
  • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
  • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
  • A61K2039/53—DNA (RNA) vaccination
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
  • A61K2039/55511—Organic adjuvants
  • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
  • A61K2039/55511—Organic adjuvants
  • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
  • A61K2039/6018—Lipids, e.g. in lipopeptides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
  • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
  • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
  • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
  • C12N2770/00011—Details
  • C12N2770/20011—Coronaviridae
  • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
  • C12N2770/00011—Details
  • C12N2770/36011—Togaviridae
  • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
  • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
  • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Definitions

• the present invention relates, a method of preparing a liquid formulation of RNA complexed with lipid nano-emulsion particles or nano-carriers. It particularly provides a method for preparation of the RNA adsorbed onto lipid nano -emulsion particles in liquid and the formulations of said RNA complexes as such.
• nucleic acids are used for therapeutic and diagnostic purposes.
• RNA-based therapy promising results have been achieved.
• various types of RNA molecules are regarded as important tools for gene therapy as well as prophylactic and therapeutic vaccination against many infectious and malignant diseases.
• RNA Nucleic acids, both DNA and RNA, have been used widely in gene therapy, either in naked or in complexed forms.
• the use of RNA is advantageous in modern molecular medicine, having some superior properties over the use of DNA.
• transfection of DNA molecules may lead to serious complications and these risks do not occur if particularly mRNAs are used instead of DNA.
• An advantage of using RNA rather than DNA is that no virus-derived promoter element has to be administered in vivo and no integration into the genome may occur and the RNA does not need to travel to the nucleus for the expression.
• RNAs as such, as pharmaceutical agents has been limited due to its sensitivity to degradation and problems of the delivery across the cell membranes upon injection in the body of animals or human subjects.
• the RNA molecules are inherently unstable due to its structural properties and degrade fast in general conditions if not stabilized.
• an object of the present invention is to provide a method for the effective delivery of disease modifying mRNA molecules in combination with novel lipid nano-emulsion particles [also called nano-carriers] forming a liquid pharmaceutical formulation, which is clinical effective, safe, scalable, and is also time- and cost-efficient. Therefore, an object of the invention is to provide a composition of said lipid nano-emulsion particles and a method of complexing mRNA molecules of interest with the particles, and such RNA molecules on being transported into a cell, a tissue or an organism generating the required therapeutic or immunological effects. A further object of the invention is to provide methods for the preparation of mRNA molecules and nano- carriers suitable for said formulations.
• the present invention has the following aspects: l. mRNA molecules and preparation thereof;
• the present invention relates to the preparation of RNA or mRNA molecules capable of expressing of a protein or peptide when delivered inside a live cell using nano-carriers.
• the said RNA being of therapeutic or prophylactic nature is useful in the pharmaceutical applications.
• the said mRNAs having sequences of the genes of interest, which may relate to antigens derived from genes of viruses, bacteria or other microorganisms or higher organisms.
• the said RNA or mRNA comprises from 50 to 50000 nucleotides, preferably having from 200 to 15000 nucleotides and more preferably having from 500 to 12000 nucleotides.
• non-coding types such as ribosomal RNA or transfer RNA and other coding RNA molecules, such as viral RNA, retroviral RNA, self-replicating RNA, small interfering RNA, microRNA, small nuclear RNA, small-hairpin RNA or a combination thereof may be used in the invention disclosed herein.
• said coding or non-coding RNA may comprise modified RNA having enhanced properties like stability in vitro and in vivo.
• the said RNA modification may refer to chemical modifications comprising backbone modifications as well as sugar modifications or base modifications.
• the said RNA maybe encoding a protein or a peptide or an antigen, which may be selected, without any restriction, from therapeutically active proteins or peptides, selected from adjuvant proteins, from tumour antigens, pathogenic antigens (e.g. selected, from animal antigens, from viral antigens, from protozoan antigens, from bacterial antigens), allergenic antigens, autoimmune antigens, or further antigens, from allergens, from antibodies, from immunostimulatory proteins or peptides or from any other protein or peptide suitable for a therapeutic application.
• a modified RNA molecule may contain nucleotide analogues/modifications, e.g. backbone modifications, sugar modifications or base modifications.
• a modification in connection with the present invention is a modification, in which the capping of RNA molecules is done at the 5’- end using enzymes in vitro.
• said liquid formulation of the invention comprises at least one RNA, wherein the RNA is an mRNA molecule, having at least one open reading frame, which encodes at least one peptide or protein.
• said modified RNA molecule is having two of more open reading frames for peptides or proteins, which aid in the replication of said RNA molecules in vivo [also called self -replicating mRNAs] and preferably, the sequence of the open reading frame in such an RNA molecule is modified as described herein.
• the said RNA comprised in said composition comprises a 5'- and/ or 3' untranslated regions (s'-UTR or 3'-UTR, respectively).
• the at least one RNA comprises at least one selected from the group consisting of a 5'-UTR, a 3'- UTR, a poly(A) sequence and/ or a poly(C) sequence. More preferably, at least one RNA comprises a 5'-CAP structure.
• a 5’-UTR is typically the part of an mRNA, which is located between the protein coding region and the 5'-terminus of the mRNA.
• a 5'-UTR of an mRNA is not translated into any amino acid sequence.
• the 5’ -UTR sequence is generally encoded by the gene, which is transcribed into the respective mRNA during the gene expression process.
• a 5'-UTR corresponds to the sequence of a mature mRNA, which is located 3' to the promoter sequence and immediately 5' to the start codon of the protein coding region.
• the said RNA of the invention comprises at least one 5'-UTR.
• At least one RNA comprises a 5'-UTR, which comprises or consists of a nucleic acid sequence derived from the 5'-UTR of an Alpha virus gene.
• at least one RNA comprises a 5'-UTR, which may be derivable from a gene that relates to an mRNA with an enhanced half-life.
• the nucleotide sequence of 5'-UTR element of an Alpha virus gene is, namely, from the Venezuelan Equine Encephalitis Virus (VEEV) strain TC-83.
• a 3’ -UTR is typically the part of an mRNA, which is located between the protein coding region and the 3'-terminus of the mRNA.
• a 3'-UTR of an mRNA is not translated into any amino acid sequence.
• the 3’ -UTR sequence is generally encoded by the gene, which is transcribed into the respective mRNA during the gene expression process.
• a 3 '-UTR corresponds to the sequence of a mature mRNA, which is located 3' to the stop codon of the protein coding region, preferably immediately 3' to the stop codon of the protein coding region, and which extends to the 5'-side of the 3'-terminus of the mRNA or of the poly(A) sequence, preferably to the nucleotide immediately 5' to the poly(A) sequence.
• the said RNA of the invention comprises at least one 3'-UTR. More preferably, at least one RNA comprises a 3 '-UTR, which comprises or consists of a nucleic acid sequence derived from the 3'-UTR of an Alpha virus gene. Preferably, at least one RNA comprises a 3'-UTR, which maybe derivable from a gene that relates to an mRNA with an enhanced half-life.
• the nucleotide sequence of 3'-UTR element of an Alpha virus gene is, namely, strain TC-83.
• said RNA of the invention further comprises a poly(A) sequence.
• the length of the poly(A) sequence may vary.
• the poly(A) sequence may have a length of about 20 up to about 300 adenine nucleotides, preferably of about 40 to about 200 adenine nucleotides.
• the said RNA comprises a poly(A) sequence of about 40 to about 60 nucleotides, most preferably 45 adenine nucleotides.
• a DNA template is prepared from a plasmid cultured in an E. coli cell line.
• the plasmid is isolated from the bacteria and enzymatically linearized to obtain the DNA template or alternatively said DNA template is obtained by the polymerase chain reaction using small amount of the plasmid or bacterial host harbouring said plasmid as the reaction source.
• a suitable phage promoter not limited to T7 RNA polymerase.
• the RNAse inhibitor may also be used to protect the RNA from degradation.
• Reaction also uses a pyrophosphtase enzyme that converts the insoluble pyrophosphate into inorganic phosphate, a by-product of in vitro transcription.
• the DNA template, enzyme mix and rNTPs are incubated under the appropriate conditions to yield the mRNA of a size between 500 and 50000 nucleotides.
• the DNA template is degraded from the reaction mixture by DNAse enzymes in the presence of salts under the appropriate conditions.
• the next step is the mRNA protection by 5’ capping. This can be achieved by chemical conjugation or enzymatic reaction.
• the crude mRNA preparation is first purified by column chromatography in the flow-through mode, binding impurities to the resin while the mRNA flows through the resin. This flow through is collected for the next step of affinity chromatography to remove the similar impurities.
• the eluate from the affinity column is concentrated and diafiltered with the hollow fibre modules and further sterilized by membrane filters. This product is used for the complexing with nano-carriers.
• the present invention relates to lipid nano-emulsion particles (also called nano-carriers) and a method for preparing it in liquid.
• the said nanocarriers comprising properties of adsorbing single strand mRNA molecules on its surfaces and allowing delivery of said mRNA molecules across the cell membranes into the cells.
• the said nano-carriers comprises at least one cationic or polycationic lipid compound, preferably as defined herein, wherein the said cationic or polycationic compound are present in a complex with other components forming stable lipid nano-emulsion particles or nano-carriers.
• the said nano-carriers of the invention preferably comprises a cationic or polycationic lipid compound, preferably DOTAP (i,2-dioleoyl-3-trimethylammonium-propane), DDA (dimethyldioctadecylammonium) or similar cationic/ polycationic lipids.
• nano-carrier typically refers to a composition of the lipid nano-emulsion particles [herein also cited as GNPs or its derivatives] comprising a cationic or polycationic compound and other components that supports the formation and stability of such complexes.
• GNPs are also known as cationic nano-emulsions (CNEs) or cationic lipid nano-emulsions (CLNEs) in the art.
• said nano-carriers have the average size, preferably in a range from 30 to 300 nm, more preferably from 50 to 200 nm. In a particularly preferred embodiment, the average size of the nano-carriers comprising or consisting of complexed RNA is from 50 to 100 nm.
• said nano-carriers with or without RNA adsorbed onto it have a poly dispersity index [PDI] relating to its size in a range from 0.150 to 0.300, more preferably from 0.170 to 0.230.
• said nano-carriers comprising or consisting of a cationic or polycationic compound have a zeta potential value in a range from -10 to -50 mV, more preferably from -25 to -35 mV.
• said nano-carriers remain stable in a suitable solvent.
• a solvent which allows dissolution of said RNA and, further components, such as buffering agents, etc as defined herein. More preferably, the solvent is volatile with a boiling point of preferably below 120 °C.
• the solvent is preferably non-toxic.
• the solvent is an aqueous solution. In the case of an organic solvent, the solvent is preferably miscible with water.
• the solvent provided may comprise a buffer, preferably selected from a buffer as defined herein.
• said nano-carriers provided may additionally contain at least one component selected, e.g., from immunostimulants, metal compounds or metal ions, surfactants, polymers or complexing agents, buffers, etc., or a combination thereof.
• the said nano-carriers provided may additionally contain a further component selected from the group of surfactants.
• group may comprise, without being limited thereto, any surfactant suitable for the preparation of a pharmaceutical composition, preferably, without being limited thereto, polysorbate, sorbitan, etc.
• said nano-carriers provided may additionally contain a further component selected from the group of non-specific immunostimulants.
• group may comprise, without being limited thereto, any non-specific immunostimulants suitable for the preparation of a pharmaceutical composition, preferably, without being limited thereto, squalene or any other similar compounds.
• the said nano-carriers provided may additionally contain a further component selected from the group of specific immunostimulants.
• group may comprise, without being limited thereto, any specific immunostimulants suitable for the preparation of a pharmaceutical composition, preferably, without being limited thereto, monophosphoryl lipid-A [MPL] or glucopyranosyl lipid-A [GLA] or any other similar adjuvant compounds.
• MPL monophosphoryl lipid-A
• GLA glucopyranosyl lipid-A
• the present invention relates a liquid formulation comprising an mRNA adsorbed onto lipid nano-emulsion particles or nano-carriers as described herein in below and said formulation comprising said mRNA at a concentration preferably between o.i and 1 mg/mL.
• said RNA or mRNA comprised in the liquid formulation is complexed at least partially with a cationic or polycationic lipid contained in said nanocarriers.
• a cationic or polycationic lipid contained in said nanocarriers Partially means that only a part of the at least one RNA molecule is complexed with a cationic or polycationic compound and that the rest of the at least one RNA molecule is in non-complexed form ("free").
• the ratio of complexed RNA to free RNA is between 25:1 (w/w) and 50:1 (w/w), more preferably is about 50:1 (w/w).
• the relative integrity is preferably determined as the percentage of full-length RNA (i.e. non-degraded RNA) with respect to the total amount of RNA (i.e. full-length RNA and degraded RNA fragments (which appear as smears in gel electrophoresis images), preferably after deduction of background noise, for example, by using a software based densitometry.
• the relative integrity of the said RNA in the liquid formulation of inventive method is at 80% and more preferable at least 90% after storage at freezing temperature for preferably at least six months.
• the biological activity of the said RNA of the liquid formulation after storage at room temperature is preferably at least 70%, more preferably at least 80% and most preferably at least 90% of the biological activity of the freshly prepared RNA.
• the biological activity is preferably determined by analysis of the amounts of protein expressed from reconstituted RNA and from freshly prepared RNA, respectively, e.g. after transfection into a mammalian cell line or into a subject. Alternatively, the biological activity may be determined by measuring the induction of an (adaptive or innate) immune response in a subject. Further, the disclosed invention provides the use of the inventive method and products in the manufacture of a pharmaceutical preparation or a vaccine.
• a pharmaceutical formulation which comprises or consists of the liquid formulation obtainable by the inventive method.
• the inventive pharmaceutical formulation comprises at least one additional pharmaceutically acceptable ingredient, such as a pharmaceutically acceptable carrier and/or vehicle.
• the inventive pharmaceutical formulation may optionally be supplemented with further components as defined above with regard to the liquid formulation.
• the inventive pharmaceutical formulation is prepared as a whole by the inventive method.
• the inventive pharmaceutical formulation may be administered by parenteral injection, more preferably by subcutaneous, intravenous, intramuscular injection.
• Sterile injectable forms of the inventive pharmaceutical formulations maybe aqueous or oleaginous suspension. These suspensions maybe formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents.
• the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent.
• These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethylcellulose or similar dispersing agents that are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions.
• a long-chain alcohol diluent or dispersant such as carboxymethylcellulose or similar dispersing agents that are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions.
• Other commonly used surfactants such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable forms may also be used for the purposes of formulation of the invention.
• the inventive pharmaceutical composition typically comprises a "safe and effective amount" of the components of the inventive pharmaceutical formulation as defined above, particularly of at least one RNA as comprised in the said formulation obtainable by the inventive method.
• a "safe and effective amount” means an amount of the at least one RNA that is sufficient to significantly induce a positive modification of a disease or disorder as defined herein.
• a "safe and effective amount” is small enough to avoid serious side-effects, that is to say to permit a sensible relationship between advantage and risk.
• the inventive pharmaceutical formulation may be used for human and also for veterinary medical purposes, preferably for human medical purposes, as a pharmaceutical formulation in general or as a vaccine.
• the pharmaceutical formulation comprises an adjuvant.
• an adjuvant may be understood as any compound, which is suitable to initiate or increase an immune response of the innate immune system, i.e. a non-specific immune response.
• the inventive vaccine when administered, preferably elicits an innate immune response due to the adjuvant, optionally contained therein.
• an adjuvant may be selected from an adjuvant known to a skilled person and suitable for the present case, i.e. supporting the induction of an innate immune response in a mammal.
• the adjuvant is preferably selected from compounds, which are known to be immune-stimulating due to their binding affinity (as ligands) to human toll-like receptor -4 [TLR4] like GLA [Glucopyranosyl Lipid Adjuvant] or MPL [Glucopyranosyl Lipid Adjuvant].
• the present invention furthermore provides several applications and uses of the formulation obtainable by the disclosed method, the inventive pharmaceutical formulation, the inventive vaccine or the inventive kit or kit of parts.
• FIGURE 1 Depicts the general structure of the pVEE plasmids [which is based on pMBi plasmid] with self-replicating mRNA expressing cassettes for different antigens as disclosed in the invention disclosed.
• FIGURE 2 SEQ ID NO: l, is the protein sequence corresponding to SARS-CoV-2 Spike Protein B.i Variant with a D614G mutantion.
• FIGURE 2-1 SEQ ID NO: 2, is the protein sequence corresponding to SARS-C0V-2 Spike Protein Wuhan- Hu-i variant [GISAID Accession No.: EPI_ISL_402i25 Virus name: hCoV-19/ Wuhan/ Hu-1/2019 Collection date: 31 Dec 2019].
• FIGURE 3 Depicts the quality of mRNA during IVT process.
• [A] shows different steps of IVT, IVT-A step: Lane 2 [2 h incubation], 3 [3 h] and 4 [4 h];
• IVT-B step Lane 5 and IVT-C step: Lane 6.
• [B] shows different steps of purification of mRNA, Lane 2 crude mRNA preparation from IVT-C, while Lane io is retentate finally obtained.
• [C] shows the final drug substance obtained from retentate, Lane 2.
• the molecular weight marker in all gels is the same having first bank of 9 kb, sixth band of 3 kb and 10th band of 0.5 kb of single strand RNA.
• FIGURE 3-1 Depicts the chromatographic profile of the purified mRNA batch sample as described in Example 3.
• FIGURE 4 Shows the SEC-HPLC profile of the purified SAR-C0V-2 spike protein mRNA construct of about 12 kb having retention time [RT] of about 8.15 minutes.
• FIGURE 5 Shows relative integrity of mRNA after adsorption onto lipid nano- emulsion particles or nano-carriers of different types.
• [A] shows the adsorption of mRNA molecules onto nano-carriers showing no movement of said mRNA molecules in electric field.
• [B] shows the RNAse protection of bound mRNA molecules to different nano-carriers. The bound mRNA molecules remain intact even after the RNAse treatment.
• FIGURE 5-1 Shows expression profile of naked mRNA and mRNA adsorbed or complexed onto the nano-carrier in the HEK 293T ells in vitro.
• FIGURE 6 Shows the immune response generated by vaccine formulations comprising the mRNA molecules and nano-carriers of the inventive method disclosed herein.
• FIGURE 7 Shows the neutralising antibody response generated by vaccine formulations comprising the mRNA molecules and nano-carriers of the inventive method disclosed herein.
• EXAMPLE 1 PLASMIDS FOR THE EXPRESSION OF mRNA MOLECULES
• NSPi to NSP4 Non Structural Proteins
• VEEV Venezuelan Equine Encephalitis Virus
• SARS C0V-2 spike protein encoding sequence is simultaneously transcribed during self -replication and then translates the viral spike protein antigens in the host cell. Alongside replication and prolonged expression of spike protein generates the long lasting booster immune responses. All plasmids were routinely maintained in the E. coli cells using the standard protocols. A representative illustration is shown in the FIGURE l, that depicts the structural elements of the pVEE plasmids containing various genes of interest, like the D614G mutant of SARS-C0V-2 spike protein gene of B.i variant as shown in FIGURE 2, among other variants of the spike proteins or antigen relevant genes of interest from other viruses and organism.
• the various mutants or variants of the SARS-C0V-2 spike protein that may be used with respective the base spike protein sequence of Wuhan-Hu-i variant [see FIGURE 2-1] are shown TABLE 1.
• the pVEE vector is based of pMBi plasmid known in the art. This vector contains T7 polymerase promoter element, 5’-UTR element, ORFs for the self-replicating non-structural proteins (NSP1-4), signal sequence, gene of interest like the spike protein, 3’ UTR element flowed by poly A tail element in a series, along with pMBi base plasmid elements and kanamycin resistance marker.
• IVT in-vitro transcription
• reaction mass about 0.975 m L of 1 M MgCl2 solution, about 10.5 mL of 25 mM of rNTPs each in solution and about 0.375 m L of 1 M dithiothreitol solution were added. Further to said reaction mass about 1.5 mL of 50 mM spermidine solution, about 7.5 mL of 250 ng/pL of template DNA solution, and about 0.75 mL of 1 ug/pL of inorganic pyrophosphatase solution were added. This was followed by about 0.21 mL of 1.5 ⁇ g/ pL of RNAse inhibitor solution, and about 0.28 mL of 2 ⁇ g/pL of T7 polymerase solution.
• the resulting reaction mass of about 38 mL was gently mixed and incubated at about 32 °C on a shaker as about 100 RPM for about 4 hours.
• This part afforded robust synthesis of mRNA from the DNA template [see FIGURE 3A Lanes 2 to 4, Lane 1 is RNA molecular weight ladder - first band is of 9 kb and the last is of 0.5 kb - which is same in all the experiments].
• Lane 1 is RNA molecular weight ladder - first band is of 9 kb and the last is of 0.5 kb - which is same in all the experiments].
• said 38-mL reaction mass was transferred to a 500-mL flask and to which about 350 mL highly pure water was added.
• This reaction mass was further supplemented with about 0.2 mL of 1 M CaCl2 solution and about 0.05 mL of 2.5 ⁇ g/pl DNAse solution.
• the resulting reaction mass of about 390 mL was gently mixed and incubated at about 32 °C on a shaker as about 100 RPM for about 30 minutes.
• This part completely removes the DNA template used in the first part [see FIGURE 3A Lanes 5].
• said 390-mL reaction mass was transferred to a 2000-mL flask and to which about 730 mL highly pure water was added.
• This reaction mass was further supplemented with about 58 mL of 1 M Tris-HCl, pH 8.0 buffer solution, about 0.225 mL of 1 M MgCl2 solution, about 2.5 mL of 1 M of KC1 solution, about 12 mL of 100 mM of GTP solution and about 7.5 mL of 32 mM of S- adenosylmethionine solution and about 0.8 mL of 1 M of dithiothreitol solution. Further to it about 0.2 mL of 1.5 ⁇ g/pL RNAse inhibitor solution and about 0.75 mL of 2 ⁇ g/pL guanyltransferase solution were added.
• Example 2 The reaction mass of Example 2 containing mRNA molecules was subjected to mRNA purification by chromatography and filtration methods.
• said of mass of about 1200 mL was supplemented with Tris-HCl and KC1 stock solutions to achieve the final concentrations of 10 mM of Tris-HCl and 250 mM of KC1 at pH 8.0.
• the first chromatographic step was used in flow through mode in which the impurities bind to the column while the mRNA molecules are collected in the flow through solution.
• said diluted solution was subjected to a pre-equilibrated column having the octylamine based highly cross-linked agarose resin [CaptoCore 700 - Cytiva] or similar resin matrix and the flow through fractions were collected, which contained the said mRNA molecules [see FIGURE 3B, Lane 2 before first step, Lane 3 after first step; see FIGURE 3-1 Chromatograph A].
• the second chromatographic step was used in affinity mode in which the mRNA molecules bind to the column while the impurities come out with the flow through fractions.
• said mass of first step of about 1000 mL was supplemented with Tris-HCl, NaCl and EDTA stock solutions to achieve the final concentrations of 10 mM of Tris-HCl, 0.8 M of NaCl and 1 mM of EDTA at pH 8.0.
• RNA drug substance of about 500 mL containing about 200 ⁇ g/mL of said mRNA [see FIGURE 3B, Lane 10]. Further said drug substance was filter sterilised using a 0.2 m membrane filtration system and stored at -80 °C until used [see FIGURE 3C, Lane 2]. Further the size exclusion HPLC analysis was performed on said drug substance using standard methods, said drug substance has retention time of about 8.15 minutes and showed more than 95% molecular purity [see FIGURE 4]. The RNA drug substance was routinely diluted or concentrated to achieve mRNA concentration of between 0.1 to 1.5 mg/mL and stored at -80 °C until further used.
• the preparation of the nano-carriers or GNPs was achieved in a three-part process.
• the oil phase was prepared using all the hydrophobic substances that form the part of the said carrier.
• to prepare about 4 mL of said oil phase about 3 g of DOTAP, about 3.7 g of sorbitan monostearate [SPAN-60] and about 3.75 g of squalene was mixed in a glass container. Said mixture was warmed ay about 65 °C till all the components got well mixed in homogenous consistency.
• about 3.7 g of polysorbate-8o was mixed with about 96 mL of 10 mM sodium citrate, pH 6.0 buffered solution, which was kept warm at 65 °C.
• both the oil and aqueous phases were mixed under high shear mixer running at about 5000 RPM for about 15 minutes. Then this mixture was passed about 10 times through high pressure homogenizer at about 30,000 psi and primed with remaining aqueous phase affording about 100 mL of nano-carrier solution.
• the said nano-carrier solution optionally contained immunostimulating substances like MPL or GLA at an amount of about 0.5 ⁇ g/ mL when desired.
• the nano -carrier GNP contained no MPL or GLA, while GNP-M contained MPL adjuvant and GNP-G contained GLA adjuvant [see TABLE 2].
• EXAMPLE 5 PREPARATION COMPLEXES OF NANO-CARRIERS AND mRNA MOLECULES
• the adsorption of mRNA molecules onto said nano-carrier were performed very careful and precise process of mixing of said mRNA solution into said nano-carrier solution forming the stable complexes.
• the ratio of nitrogen [present on the DOTAP molecules] to phosphate [present on the RNA molecules; N:P ratio] was taken as a measure of association of said mRNA molecules to said nano-carrier particles as the mRNA molecules being negatively charged while the DOTAP molecules positively charged, it leading to adsorption of said mRNA molecules on said nano-carriers.
• N:P ratio between 1 and 150 DOTAP to RNA amounts were tried, keep the amount of RNA constant.
• the said nanocarrier solution of Example 4 is diluted to about 6 mg/ mL of DOTAP with 10 mM sodium citrate, pH 6.0 solution. Then, about 50 mL of this diluted nano-carrier solution was taken in a 1000-mL container and placed on an orbital shaker rotating at between 70 and 120 RPM. Then about 50 mL of mRNA solution [RNA drug substance] as prepared in Example 3 was added slowing using a syringe pump in about 5 minutes under the constant stirring condition at temperature of about 2-8 °C.
• RNA molecules adsorbed onto the nano -carrier particles and changes in the properties of said nano-carrier were measured by dynamic light scattering on Zetasizer Nano system [Malvern Panalytical]. TABLE 2 provides changes observed in said parameters of the nano-carriers upon adsorption of RNA molecules.
• the integrity of the mRNA molecules as such or after extraction from the nano-carriers was determined by the formaldehyde denaturing agarose gel electrophoresis using methods known in the art. Briefly, mRNA samples were prepared in MOPS buffer with formaldehyde, ethidium bromide and a tracking dye like methylene blue by heating said mixture at about 70 °C for about 30 minutes. Then the samples were separated on 1 % agarose gels upon completion of desired run of the samples in the gel and view under UV illumination and images preserved for the record. For the extraction of the mRNA molecules from the nano-carrier, said complexes were subjected to phenol-chloroform extraction.
• FIGURE 5A The results are shown FIGURE 5A, wherein naked control mRNA runs on the gel corresponding to size of about 12 kb [Lane 3], while the RNA complexed with nano-carriers stay in the loading wells [Lanes 5 - GNP, 8 - GNP-M and 11 GNP- G], while the extracted mRNA molecules from nano-carriers also run at about 12 kb also [Lanes 6 - GNP, 9 - GNP-M and 12 GNP- G] without any degradation of its integrity, proving the integrity of the mRNA molecules in association with the nano-carriers.
• the integrity of the mRNA was further tested with RNAse protection assays.
• mRNA samples with or without nano-carriers were subjected to RNAse treatment and analysed by formaldehyde agarose gel electrophoresis.
• naked mRNA was treated with RNAse and showed complete degradation Lane 3 compared to untreated mRNA in Lane 2 control.
• Lane 4 is GNP without treatment
• Lane 5 is GNP treated with RNAse, in both the cases RNA remains attached to GNP particles and remains in the loading wells, showing protection of mRNA in complex with the nano-carrier.
• the mRNA extracted from the RNAse treated GNP particles [see Lanes 7, 11 and 15] and untreated GNP particles [see Lanes 6, 10 and 14] showed band size a bit above the 9 kb marker band indicating that said mRNA is intact without loss of integrity even after the RNAse treatment of the said complex.
• the amount of mRNA was determined in different samples by the ultrasensitive Qunati-IT RiboGreen RNA Assay Kit [ThermoFisher-Invitrogen] as per the manufacturers protocol. Briefly, when bound to free mRNA molecules the RiboGreen reagent has absorption and emission maxima at 500 nm and 525 nm, respectively. The detection sensitivity of this method is between 1 and 200 ng/ mL of RNA in solution. Further the extracted RNA associated with lipid nano-carrier particles can also be easily detected using this method.
• EXAMPLE 7A EXPRESSION PROTEIN IN HEK CELLS BY RNA ADSORBED ONTO NANO-CARRIERS
• HEK 293T cells were cultured for about 24 hours in 1 mL DMEM with FBS in cell culture plates and then treated as disclosed and incubated at 37 °C in presence of 5% CO2 for about 48 hours. After incubation, supernatant from the cell monolayer was discarded, and adhered cells were lysed with the 200 ⁇ L lysis buffer. The lysed solution was subjected to western blot using a SARS-C0V-2 (COVID- 19) spike antibody for detection of the expressed spike protein. Sandwich ELISA with SARS-C0V-2 (COVID-19) spike antibodies was performed to estimate the expressed spike protein in the cell lysate.
• EXAMPLE 8 IMMUNOGENICITY STUDIES
• the vaccine solution obtained in Example 5 was subjected to the immunogenicity studies to determine the immunogen producing properties of the mRNA molecules adsorbed onto said nano-carriers.
• said vaccine solution or control solutions were injected to C57BL/6 or BALB/c mouse populations. About six mice were used per group as depicted in FIGURE 6.
• the first control group was injected with the plain diluent or buffer solution only.
• the second control group was injected with naked mRNA equivalent to its amount present in the test vaccine solution
• the nano-carrier control groups were injected with naked nano-carrier GNP or GNP-M or GNP-G equivalent to its amount present in the test vaccine solution.
• the first test group was injected with about 100 pL of test vaccine solution containing about 5 pg of mRNA complexed with GNP.
• the second test group was injected with about 100 pL of test vaccine solution containing about 5 pg of mRNA complexed with GNP-M.
• the third test group was injected with about 100 pL of test vaccine solution containing about 5 pg of mRNA complexed with GNP-G. All the studies groups were then tested for production of antibodies against the SARS-C0V-2 spike protein on the 14, 28 and 43 days after the injection of said materials.
• the mouse group injected with the vaccine solutions [i.e., the mRNA complexed with GNP, GNP-M or GNP-G] showed marked increase in the production of antibodies against the spike protein compared to the naked mRNA injected group, while other control groups did not produce any antibody against the spike protein.
• the IgG antibodies in different groups were detected by standard protocols using ELISA assays. This data discloses the stability, immunogenicity and suitability for the clinical applications of said vaccine solution wherein mRNA is adsorbed onto the lipid nanoemulsion particles or nano -carriers.
• the SARS-COV-2 surrogate vims neutralization test [sVNT] was performed using the cPass SARS-C0V-2 Neutralization Antibody Detection Kit [Genscript]. The assays were performed as per the manufacturer’s protocol. Briefly, samples were diluted 10 times in dilution buffer. The diluted samples along with the positive and negative controls provided in the kit were incubated with equal volumes of 1000 fold HRP conjugated RBD supplied in the kit. Then the incubation was done at 37 °C for about 30 min. Then about 100 uL of all samples and controls are taken in the ACE-2 protein coated wells provided with the kit. The reactions were allowed in dark for about 15 min at 37 °C.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• General Health & Medical Sciences (AREA)
• Virology (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Epidemiology (AREA)
• Molecular Biology (AREA)
• Communicable Diseases (AREA)
• Dispersion Chemistry (AREA)
• Mycology (AREA)
• Biophysics (AREA)
• Microbiology (AREA)
• Immunology (AREA)
• Pulmonology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Oncology (AREA)
• Dermatology (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)
• Engineering & Computer Science (AREA)
• Biotechnology (AREA)
• Genetics & Genomics (AREA)
• Biochemistry (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (8)

Applications Claiming Priority (2)

Publications (1)

Family

ID=84920187

Family Applications (1)

Country Status (11)

Cited By (10)

Families Citing this family (1)

Family Cites Families (2)

• 2021
  • 2021-07-13 IN IN202121031414A patent/IN202121031414A/en unknown
• 2022
  • 2022-07-08 AU AU2022310435A patent/AU2022310435A1/en active Pending
  • 2022-07-08 WO PCT/IN2022/050624 patent/WO2023286076A1/en not_active Ceased
  • 2022-07-08 KR KR1020247004893A patent/KR20240035836A/ko active Pending
  • 2022-07-08 JP JP2024501633A patent/JP2024525709A/ja active Pending
  • 2022-07-08 US US18/578,881 patent/US20240325522A1/en active Pending
  • 2022-07-08 EP EP22841629.3A patent/EP4351521A4/en active Pending
  • 2022-07-08 CA CA3226213A patent/CA3226213A1/en active Pending
• 2024
  • 2024-01-03 ZA ZA2024/00149A patent/ZA202400149B/en unknown
  • 2024-01-12 CO CONC2024/0000205A patent/CO2024000205A2/es unknown
  • 2024-01-15 CL CL2024000120A patent/CL2024000120A1/es unknown

Non-Patent Citations (4)

Also Published As

Similar Documents

Legal Events